OncLive Staff

Articles

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023

Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating this regimen into the frontline setting for this population.

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

April 20th 2023

Drs Gushchin and Diaz-Montes discuss findings from the HOT trial evaluating health-related quality of life outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary ovarian cancer.

Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience

April 17th 2023

Dr Desai discusses the aspects of his oncology fellowship experience that have had the greatest influence on his career growth, the role of mentorship throughout his fellowship and transition to a full-time faculty position, and his advice for current and future oncology fellows.

Risk Classification, Mutational Analysis Are Key in Informing AML Management

April 14th 2023

During an OncLive® workshop titled Key Updates in the Management of Acute Myeloid Leukemia and Their Application in Clinical Practice, moderated by Naval Daver, MD, faculty reviewed updates to the classification of acute myeloid leukemia and its effects on the treatment paradigm and provided insight on the management of adverse-risk and secondary acute myeloid leukemia.

FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer

April 13th 2023

Dr Gilbert discusses the FDA approval of dostarlimab in patients with endometrial cancer, key efficacy data from the GARNET trial, and how this agent bolsters the endometrial cancer treatment paradigm.

Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

April 10th 2023

Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

April 6th 2023

Drs Mercado and Kovacs discuss the importance of multidisciplinary approaches to lung cancer screening and management, barriers to lung cancer screening that affect how early certain patients are diagnosed with this disease, and where the future of lung cancer detection and treatment is headed.

Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer

April 3rd 2023

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Dr Bidard discusses the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, key efficacy and safety data from the EMERALD trial, and the importance of testing for ESR1 mutations in patients with ER-positive, HER2-negative disease.

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.

Camidge and Jalal on Setting up an Infrastructure for Success in Life and Work

March 23rd 2023

In this episode of ‘How This is Building Me,’ Camidge sits down with Jalal to discuss her transition from life in Jordan to Indianapolis, Indiana, the realities of being a mother in medicine, the importance of transparency in academia, and more.

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.

Milner, Dalal, and Ligon Discuss Stem Cell Transplant Methods, Results, and Risk Factors in Pediatric Patients

March 13th 2023

Drs Milner, Dalal, and Ligon discuss hematopoietic stem cell transplant in children with severe aplastic anemia, graft failure risk factors in children receiving hematopoietic cell transplant for non-malignant disorders, and the use of mediports for CAR T-cell infusion.

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

March 9th 2023

Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023

Drs Khushalani, Dietrich, Luke, and Patel discuss the nuances of defining resectability in cutaneous squamous cell carcinoma, the evolving treatment paradigm of resectable disease, and how to translate updated data with cemiplimab into clinical practice.

Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma

March 2nd 2023

Dr Jakubowiak discusses interim findings from the ATLAS trial of lenalidomide plus carfilzomib and dexamethasone vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023

Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.

Finding and Leveraging CEACAM5 Presents Opportunities and Pitfalls

February 24th 2023

As carcinoembryonic antigen–related cell adhesion molecule 5 continues to show promise a target in patients with non–small cell lung cancer, refinements in testing and the understanding of the implications of its inhibition remain under investigation.

Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management

February 23rd 2023

Dr Mascarenhas discusses established standards of care and ongoing research with JAK inhibitors in patients with myelofibrosis; the available frontline treatment options in this disease; and the nuances of myelofibrosis treatment sequencing.